Original title: Disability caused by multiple sclerosis is associated with the number of extra cranial venous stenoses: possible improvement by venous angioplasty. Results of a prospective study. Reference: M Denislic et al. Phlebology, doi: 10.1258/phleb.2012.012065. Multiple Sclerosis (MS) is considered a chronic inflammatory disease, progressive and immuno-mediated, demyelinating of the central nervous system. Its primary cause is still<a href="https://solaci.org/en/2012/12/07/n-3298/" title="Read more" >...</a>
Angioplasty for the erectile dysfunction
Original title: Zotarolimus-Eluting Peripheral Stents for the Treatment of Erectile Dysfunction in Subjects With Suboptimal Response to Phosphodiesterase-5 Inhibitors. Reference: Jason H. Rogers et al. J Am Coll Cardiol 2012. Article in press Up to 52% of men between 40 – 70 years old present some degree of erectile dysfunction, and 50% of these men get a suboptimal<a href="https://solaci.org/en/2012/11/30/n-3844/" title="Read more" >...</a>
Again in the bifurcation, less is more.
It has been reported that the two stents technique is not superior to a provisional stent when treating bifurcations. However, the optimal approach to rescue a secondary branch (SB) when initially opting for provisional stenting has not been established. The aim of this study was to determine angioplasty indication using balloon or stent for<a href="https://solaci.org/en/2012/11/20/n-3788/" title="Read more" >...</a>
The use of a paclitaxel eluting balloon in small vessels
Original title: A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. The BELLO (Balloon Elution and Late Loss Optimization) Study Reference: Referencia: Azeem Latib et al J Am Coll Cardiol 2012;()doi:10.1016/j.jacc.2012.09.020 The utility of paclitaxel-eluting balloons to treat in-stent restenosis is known but data for novo lesions is more limited. <a href="https://solaci.org/en/2012/11/16/n-3774/" title="Read more" >...</a>
Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents
The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,<a href="https://solaci.org/en/2012/10/01/n-3935/" title="Read more" >...</a>